Expression of glucagon-like peptide 1 receptor and its effects on biologic behavior in pancreatic neuroendocrine tumors

Pancreas

Volumn 43, Issue 1, 2014, Pages 1-6

  Cases, Ana Ines ^a   Ohtsuka, Takao ^a   Fujino, Minoru ^a   Ideno, Noboru ^a   Kozono, Shingo ^a   Zhao, Ming ^a   Ohuchida, Kenoki ^a   Aishima, Shinichi ^a   Nomura, Masatoshi ^a   Oda, Yoshinao ^a   Mizumoto, Kazuhiro ^a   Tanaka, Masao ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

GLP 1; GLP 1R; PNETs

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SPECIFIC SURVIVAL; FEMALE; GASTRINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INSULINOMA; ISOTOPE LABELING; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; YOUNG ADULT;

ADULT; AGED; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; RECEPTORS, GLUCAGON; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84891549528     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3182a71537     Document Type: Article

References (22)

1. Fischer L, Kleeff J, Esposito I, et al. Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. Br J Surg. 2008;95(5):627-635.
2. Panzuto F, Nasoni S, Falconi M, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer. 2005;12(4):1083-1092. (Pubitemid 41815799)
3. Ekeblad S, Skogseid B, Dunder K, et al. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res. 2008;14(23):7798-7803.
4. Reubi JC,Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2003;30(5):781-793. (Pubitemid 36612963)
5. Reubi JC, Macke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med. 2005;46(suppl 1): 67S-75S. (Pubitemid 47619021)
6. Li Y, Tweedie D, Mattson MP, et al. Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. J Neurochem. 2010;113(6):1621-1631.
7. Drucker DJ. Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology. 2003;144(12):5145-5148. (Pubitemid 37476039)
8. Gier B, Matveyenko AV, Kirakossian D, et al. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras (G12D) mouse model. Diabetes. 2012;61(5): 1250-1262.
9. Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141(1):150-156.
10. Ikenaga N, Ohuchida K, Mizumoto K, et al. Characterization of CD24 expression in intraductal papillary mucinous neoplasms and ductal carcinoma of the pancreas. Hum Pathol. 2010;41(10):1466-1474.
11. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131-2157. (Pubitemid 46711096)
12. Connolly BM, Vanko A, McQuade P, et al. Ex vivo imaging of pancreatic beta cells using a radiolabeled GLP-1 receptor agonist. Mol Imaging Biol. 2012;14(1):79-87.
13. Furukawa T, Kuboki Y, Tanji E, et al. Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci Rep. 2011;1:161.
14. Reubi JC. Peptide receptor expression in GEP-NET. Virchows Arch. 2007;451:(suppl 1):S47-S50. (Pubitemid 47283376)
15. Korner M, Stockli M, Waser B, et al. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med. 2007;48(5):736-743. (Pubitemid 47604973)
16. Tsutsumi K, Ohtsuka T, Mori Y, et al. Analysis of lymph node metastasis in pancreatic neuroendocrine tumors (PNETs) based on the tumor size and hormonal production. J Gastroenterol. 2012;47: 678-685.
17. Yabe D, Seino Y. Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and A cell preservation. Prog Biophys Mol Biol. 2011;107(2):248-256.
18. Perfetti R, Zhou J, Doyle ME, et al. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology. 2000;141(12):4600-4605. (Pubitemid 32055138)
19. Miyazaki J, Araki K, Yamato E, et al. Establishment of a pancreatic beta cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter isoforms. Endocrinology. 1990;127(1):126-132. (Pubitemid 20228111)
20. Cornu M, Thorens B. GLP-1 protects A-cells against apoptosis by enhancing the activity of an IGF-2/IGF1-receptor autocrine loop. Islets. 2009;1(3):280-282.
21. Sano H, Terasaki J, Mishiba Y, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, suppresses pancreatic A-cell destruction induced by encephalomyocarditis virus. Biochem Biophys Res Commun. 2011;404(3):756-761.
22. Tsuboi T, da Silva Xavier G, Holz GG, et al. Glucagon-like peptide-1 mobilizes intracellular Ca2+ and stimulates mitochondrial ATP synthesis in pancreatic MIN6 beta-cells. Biochem J. 2003;369(Pt 2): 287-299. (Pubitemid 36174198)